AstraZeneca vaccine: Government to face compliance challenge if jab advice changes

AstraZeneca vaccine: Government to face compliance challenge if jab advice changes

AstraZeneca: Sister of blood clot victim urges UK to get jabbed

When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.

Blood clotting cases have concerned authorities across Europe, who have identified a loose association with the AstraZeneca jab. They have reacted with caution, attaching age limits to dosages. The UK has followed suit, leading to warnings about compliance should ministers attempt to “walk back” advice.

Although national authorities still assert the Covid jab is safe and effective, the Joint Committee on Vaccination and Immunisation (JCVI) has led with caution.

New Government policy will limit AstraZeneca rollout to over-30s only, with everyone under the threshold offered an alternative.

Authorities have advised GP-led sites to cancel incoming appointments for this same group.

Professor Wei Shen Lim, The JCVI’s COVID-19 Chair, said his organisation wanted a safety-first approach.

But he added there is a clear benefit for the “majority of the population”.

He said in a statement: “Safety remains our number one priority.

“Based on the available data and evidence, JCVI has advised that it is preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the AstraZeneca vaccine where available.

“This weighs up the risks of being seriously ill or dying from COVID-19 against the extremely small risk of a serious adverse event.”

“The COVID-19 vaccines have already saved thousands of lives and the benefit for the majority of the population is clear – if you are offered a vaccine, you should take it.”

The JCVI has changed its advice while investigations continue into the vaccine’s association with blood clots.

As such, the research could conclude the jab is ultimately safe.

In this case, an expert has warned the Government may struggle to regain public vaccination compliance.

‘There are risks with other vaccines’ Dr Amir defends AstraZeneca – VIDEO
AstraZeneca vaccine side effects: Blood clot risk may be ‘age related’ – ANALYSIS
Blood clot symptoms: How long do blood clots take to form? – EXPLAINER

Speaking to, Dr Charlie Easmon, director of Your Excellent Health Service, said the AstraZeneca vaccine’s reputation has suffered in the UK.

He added the Government risks low public compliance if it walks back its advice.

Dr Easmon said: “I think the AZ vaccine has lost this race in the UK in that AZ stopped their own trial in the young, and the MHRA and JCVI have advised under 30s be given a different vaccine.

“You cannot ‘walk back’ advice like that and expect public confidence and compliance.”

The incidence of thromboembolic events, specifically Cerebral Venous Sinus Thrombosis (CVST), among those who received the AstraZeneca jab remains low.

Just 79 people in the more than 20 million recipients experienced clotting issues.

Of those, 19 people have died, while others spent time in the hospital.

The Medicines and Healthcare products Regulatory Agency (MHRA) estimates an incidence rate of four in one million, close to the non-vaccinated average.

Source: Read Full Article